Leerink Partners is bearing high on Mckesson Corporation (MCK) despite its recent price pullback and maintains a $785 Price Target. The investment firm Triad Wealth Partners also accentuated its confidence in MCK, acquiring 1,944 more shares. Evercore ISI and BofA expressed concerns over growth which resulted in lower price targets. Amid these developments, there have been talks of a CFO transition sparking discussions on capital allocation and valuation, potential GLP-1 pricing pressure, and hinting at credit agreements. There has also been a recent surge in institutional ownership touching 90%, hinting at the stock's immense potential. Despite this, the stock experienced a dip post earnings report. The company divested Norwegian operations, possibly owing to the strategic focus on core areas. Bullish market sentiments revolve around robustness in pharmaceutical distribution and strategies pointing towards growth. MCK showed significant earnings growth, prompting analysts to reassess its valuation. Meanwhile, talks about McKesson stock surging 17% in a single day and the company's ability to defy governmental pressure have been swirling around.
